EGFR and lung adenocarcinoma: We show six drugs that are common treatments for lung adenocarcinoma, and the results showed that all six drugs, cisplatin (Chemotherapy drug), 5-fluoropyrimidine (Chemotherapy drug), paclitaxel (Chemotherapy drug), erlotinib (targeting drug, EGFR inhibitor), gefitinib (targeting drug, EGFR-TK inhibitor), and vincristine (Chemotherapy drug), may have better efficacy in patients with LUAD in cluster 2 (Supplementary Fig. S6A–F).